Vireo Growth stock analysis
Vireo Growth (VREOF) Stock Price & Analysis
VREOF Stock Chart & Stats
- Day’s Range
- $6.42 - $6.80
- 52-Week Range
- $6.40 - $21.75
- Previous Close
- $6.74
- Volume
- N/A
- Average Volume (3M)
- 38.25K
- Market Cap
- $350.60M
- Enterprise Value
- $1.27B
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- $24.73M
- Price to Earnings (P/E)
- ―
- Beta
- 0.33
- Next Earnings
- Mar 24, 2027 (Est.)
- EPS Estimate
- 0.26
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Vireo Growth News
VREOF FAQ
What was Vireo Growth’s price range in the past 12 months?
What is Vireo Growth’s market cap?
When is Vireo Growth’s upcoming earnings report date?
How were Vireo Growth’s earnings last quarter?
Is Vireo Growth overvalued?
Does Vireo Growth pay dividends?
What is Vireo Growth’s EPS estimate?
How many shares outstanding does Vireo Growth have?
What happened to Vireo Growth’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vireo Growth?
What is the TipRanks Smart Score and how is it calculated?
Vireo Growth Stock Smart Score
Company Description
Vireo Growth
Vireo Health International, Inc. is a holding company, which engages in the cultivation, production, and sale of medical cannabis. Its products include medical marijuana extracts in the form of oils, vaporizers, and capsules. The company was founded on November 23, 2004 and is headquartered in Minneapolis, MN.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- CEO
- Amber Shimpa
- Employees
- 490
- Website
- www.goodnessgrowth.com
- Address
- 885 West Georgia Street,Suite 2200, HSBC Building, Vancouver, BC, V6C 3E8, CA
Vireo Growth (VREOF) Earnings & Revenues
VREOF Company Deck
VREOF Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by 177% year-over-year reported revenue growth, 68.1% adjusted EBITDA growth, improving operating income, a more than $1 billion annualized GAAP revenue run rate, successful acquisitions, strong Florida momentum, and formal near-term guidance. The main challenges were a temporary Minnesota supply-driven decline, seasonality, regulatory approval requirements, lower margins in competitive markets, moderate same-store growth amid cannabis price declines, and ongoing regulatory and acquisition-timing uncertainty.
View all VREOF earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 1 | 0 | 11 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| TSE:NU.HNeutriSci International | ||
| TSE:ZYUSZYUS Life Sciences | ||
| TSE:HERBLuff Enterprises | ||
| TSE:STRC.XHash Corporation |













